<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981575</url>
  </required_header>
  <id_info>
    <org_study_id>HM20014419</org_study_id>
    <secondary_id>DMCRN</secondary_id>
    <nct_id>NCT03981575</nct_id>
  </id_info>
  <brief_title>Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)</brief_title>
  <official_title>Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Insitut de Myologie Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximillians University, Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NEMO Clinic, Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the&#xD;
      present study seeks to overcome insufficient data on natural history; lack of reliable&#xD;
      biomarkers; and incomplete characterization and limited biological understanding of the&#xD;
      phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the&#xD;
      reliability by making further refinements in our sample collection and analysis procedures by&#xD;
      developing strategies for managing patient heterogeneity going forward.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 700 adult participants (18 to 70 years old, inclusive) with DM1 will be&#xD;
      enrolled at 15 centers (up to 70 patients will be recruited at each site). No treatment will&#xD;
      be administered as part of this study. Participants will receive standard of care as&#xD;
      determined by the investigators. Study visits occur at baseline/0 months, 12 months, and 24&#xD;
      months. Few restrictions are placed on participation in the study because the investigators&#xD;
      aim to capture the full spectrum of disease severity. Studies of splicing biomarkers in&#xD;
      muscle biopsy samples will be conducted on a subset of 95 participants. These participants&#xD;
      will have an additional study visit at 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">April 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ambulation over 24 months as measured by the 10 meter walk (m/s).</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>10 meter walk will be measured (m/s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in respiratory function over 24 months as measured by spirometry, specifically the supine forced vital capacity (FVC).</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Supine forced vital capacity (% predicted)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent splicing of DM1-affected splice events</measure>
    <time_frame>3 months</time_frame>
    <description>RNA sequenced of muscle biopsy samples collected at two different times will be combined and used to calculate a percent splicing index (PMI)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Myotonic Dystrophy 1</condition>
  <arm_group>
    <arm_group_label>Study Visits</arm_group_label>
    <description>Patients will receive standard of care as determined by their treating physician. Study visits occur at baseline/0 months, 12 months, and 24 months</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The biopsy sub-study will examine RNA splicing defects that are characteristic of DM1.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        DM1 has a prevalence rate of approximately 1 per 2,300. There are no expected gender&#xD;
        differences. Both men and women will be selected for this study.&#xD;
&#xD;
        Children with DM1 are not included in this project because the pathophysiological basis of&#xD;
        congenital and childhood DM1 appears to be mechanistically distinct.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age 18 to 70 (inclusive)&#xD;
&#xD;
          -  Competent to provide informed consent&#xD;
&#xD;
          -  Clinical diagnosis of DM1 based on research criteria1 or positive genetic test&#xD;
&#xD;
          -  Comment: The clinical research criteria require myotonia, muscle weakness in a&#xD;
             characteristic distribution, and history of similar findings in a first degree&#xD;
             relative. Genetic testing confirmed the diagnosis of DM1 in &gt; 99% of individuals who&#xD;
             satisfied these criteria.2&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Symptomatic renal or liver disease, uncontrolled diabetes or thyroid disorder, or&#xD;
             active malignancy other than skin cancer.&#xD;
&#xD;
          -  Current alcohol or substance abuse&#xD;
&#xD;
          -  Concurrent enrollment in clinical trial for DM1, or participation in trial within 6&#xD;
             months of entry.&#xD;
&#xD;
          -  Concurrent pregnancy or planned pregnancy during the course of the study.&#xD;
&#xD;
          -  Concurrent medical condition that would, in the opinion of the investigator or&#xD;
             clinical evaluator, compromise performance on study measures.&#xD;
&#xD;
          -  Note: non-ambulatory participants are not excluded, but are limited to &lt;15% of&#xD;
             enrollment.&#xD;
&#xD;
        Inclusion criteria for participants in the muscle biopsy sub-study:&#xD;
&#xD;
        • Of the 95 patients undergoing the tibialis anterior muscle biopsy, at least half will&#xD;
        have at least moderate weakness of ankle dorsiflexion, defined as MRC score ≤ 4+. This is&#xD;
        in order to obtain a muscle tissue sample in a person more severely affected with myotonic&#xD;
        dystrophy. Approximately 10 patients at each site will undergo the muscle biopsy.&#xD;
&#xD;
        Exclusion criteria for 95 participants in the muscle biopsy sub-study:&#xD;
&#xD;
          -  Known CTG repeat expansion size less than 100 repeats, unless there are clear cut&#xD;
             signs of limb weakness and muscle wasting. This is in order to obtain a muscle tissue&#xD;
             sample in a person more severely affected with myotonic dystrophy.&#xD;
&#xD;
          -  Use of anticoagulant such as warfarin or a direct oral anticoagulant (e.g. dabigatran)&#xD;
             due to the increased risk of bleeding.&#xD;
&#xD;
          -  Use of aspirin or non-steroidal anti-inflammatory agents should be discontinued 3 days&#xD;
             prior to the biopsy procedure, if possible.&#xD;
&#xD;
          -  Platelet count &lt;50,000 (if known) due to the increased risk of bleeding.&#xD;
&#xD;
          -  History of a bleeding disorder due to the increased risk of bleeding.&#xD;
&#xD;
          -  Advanced wasting of tibialis anterior (TA) muscle that precludes needle muscle biopsy&#xD;
             in order to ensure that a sample taken would be of muscle and not just fat and fascia.&#xD;
&#xD;
          -  Previous muscle biopsy of either TA in order to provide muscle tissue samples of&#xD;
             non-biopsied muscles.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Thornton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Johnson, MD</last_name>
    <phone>804-552-0014</phone>
    <email>nicholas.johnson@vcuhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica St Romain</last_name>
    <phone>804-828-8778</phone>
    <email>jessica.stromain@vcuhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Standford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana McDonell</last_name>
      <phone>650-407-7912</phone>
      <email>danamc@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>National Institute of Health NINDS</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Neuromuscular Reference Center Institute of Myology</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Bazzez, MD</last_name>
      <email>guillaume.bassez@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Guilaume Bazzez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedikt Schoser</last_name>
      <phone>+49 (0)89 4400 57400</phone>
      <email>max.mustermann@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Benedikt Schoser, FEAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEMO</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Mauro</last_name>
      <email>luca.mauro@centrocliniconemo.it</email>
    </contact>
    <investigator>
      <last_name>Valeria Sansone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baziel vanEngelen</last_name>
      <phone>(024) 366 8374</phone>
      <email>Baziel.vanEngelen@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Baziel van Engelen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Turner</last_name>
      <email>chris.turner7@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Chris Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 2, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myotonic Dystrophy</keyword>
  <keyword>END DM-1</keyword>
  <keyword>Muscular Dystophy</keyword>
  <keyword>DMCRN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Aggregated and deidentified data will be shared with qualified investigators upon majority approval of the DMCRN investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

